Shield Therapeutics plc
STX.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.02 | -0.01 | -0.01 |
| FCF Yield | -28.78% | -82.78% | -122.52% | -20.67% |
| EV / EBITDA | -2.41 | -1.81 | -0.43 | -4.47 |
| Quality | ||||
| ROIC | -91.09% | -83.89% | -229.43% | -48.72% |
| Gross Margin | 41.97% | 30.78% | 36.32% | 35.48% |
| Cash Conversion Ratio | 0.33 | 1.12 | 0.64 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | 66.07% | 104.99% | -19.10% | 28.31% |
| Free Cash Flow Growth | 82.45% | -98.96% | -7.13% | -1,221.29% |
| Safety | ||||
| Net Debt / EBITDA | -0.93 | -0.21 | -0.07 | 0.68 |
| Interest Coverage | -5.82 | -38.22 | -79.09 | -2,550.63 |
| Efficiency | ||||
| Inventory Turnover | 3.23 | 2.83 | 1.70 | 0.60 |
| Cash Conversion Cycle | -57.26 | 261.59 | 208.06 | -529.30 |